Yasheng Group
Multiple myeloma and other cancer treatment
Overview
Raised: $3,250
Rolling Commitments ($USD)
08/19/2023
$14
2021
Healthcare & Pharmaceuticals
Biotech
B2B
Medium
High
Summary Profit and Loss Statement
FY 2022 | FY 2021 | |
---|---|---|
Revenue |
$18,588,589 |
$14,013,905 |
COGS |
$13,001,365 |
$10,000,845 |
Tax |
$0 |
$0 |
| ||
| ||
Net Income |
$5,307,372 |
$3,717,185 |
Summary Balance Sheet
FY 2022 | FY 2021 | |
---|---|---|
Cash |
$4,176,049 |
$3,752,420 |
Accounts Receivable |
$965,616 |
$996,258 |
Total Assets |
$7,652,124 |
$7,862,556 |
Short-Term Debt |
$0 |
$0 |
Long-Term Debt |
$0 |
$0 |
Total Liabilities |
$0 |
$0 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual